NASDAQ:IMMU - Immunomedics Stock Price, Price Target & More

$16.60 -0.10 (-0.60 %)
(As of 04/20/2018 02:06 PM ET)
Previous Close$16.70
Today's Range$16.34 - $16.79
52-Week Range$5.00 - $18.93
Volume514,789 shs
Average Volume2.17 million shs
Market Capitalization$2.80 billion
P/E Ratio-20.57
Dividend YieldN/A
Beta1.62

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody; and a collaboration agreement with University of Wisconsin Carbone Cancer Center to expand IMMU-132 into prostate cancer. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:IMMU
CUSIP45290710
Phone973-605-8200

Debt

Debt-to-Equity Ratio1.20%
Current Ratio1.26%
Quick Ratio1.26%

Price-To-Earnings

Trailing P/E Ratio-20.57
Forward P/E Ratio-17.29
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.09 million
Price / Sales890.54
Cash FlowN/A
Price / CashN/A
Book Value($0.54) per share
Price / Book-30.74

Profitability

EPS (Most Recent Fiscal Year)($0.81)
Net Income$-153,200,000.00
Net Margins-7,187.83%
Return on EquityN/A
Return on Assets-76.04%

Miscellaneous

Employees138
Outstanding Shares165,770,000

How to Become a New Pot Stock Millionaire

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics (NASDAQ:IMMU) issued its quarterly earnings results on Thursday, February, 8th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.09. The biopharmaceutical company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.90 million. View Immunomedics' Earnings History.

What price target have analysts set for IMMU?

3 equities research analysts have issued 1 year price objectives for Immunomedics' shares. Their forecasts range from $15.00 to $27.00. On average, they expect Immunomedics' share price to reach $21.00 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 28,374,585 shares, an increase of 9.8% from the March 15th total of 25,844,557 shares. Based on an average daily volume of 2,281,782 shares, the short-interest ratio is presently 12.4 days. Approximately 20.3% of the company's shares are sold short.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:
  • Dr. David M. Goldenberg, Former Founder (Age 80)
  • Mr. Michael R. Garone, CFO, Principal Accounting Officer & VP of Fin. (Age 59)
  • Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)
  • Ms. Phyllis Parker, Director of Admin.
  • Dr. Chau Cheng, Sr. Director of Investor Relations & Corp. Sec.

Has Immunomedics been receiving favorable news coverage?

News headlines about IMMU stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immunomedics earned a coverage optimism score of 0.12 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.41 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $16.60.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $2.80 billion and generates $3.09 million in revenue each year. The biopharmaceutical company earns $-153,200,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Immunomedics employs 138 workers across the globe.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]


MarketBeat Community Rating for Immunomedics (IMMU)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  211 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  386
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Immunomedics (NASDAQ:IMMU) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Immunomedics in the last 12 months. Their average twelve-month price target is $21.00, suggesting that the stock has a possible upside of 26.51%. The high price target for IMMU is $27.00 and the low price target for IMMU is $15.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.00$21.00$15.50$15.50
Price Target Upside: 26.51% upside15.96% upside32.93% upside32.93% upside

Immunomedics (NASDAQ:IMMU) Consensus Price Target History

Price Target History for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ:IMMU) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2018Jefferies GroupBoost Price TargetBuy$22.00 -> $27.00MediumView Rating Details
7/24/2017CowenReiterated RatingOutperform$15.00LowView Rating Details
5/5/2017Wells FargoUpgradeMarket Perform -> OutperformHighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Immunomedics (NASDAQ:IMMU) Earnings History and Estimates Chart

Earnings by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ:IMMU) Earnings Estimates

2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.19)($0.19)($0.19)

Immunomedics (NASDAQ IMMU) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2018Q2 2018($0.10)($0.19)$0.90 million$0.60 millionViewN/AView Earnings Details
11/9/2017Q1 2018($0.10)($0.16)$0.90 million$0.69 millionViewN/AView Earnings Details
8/16/2017Q4 2017($0.12)($0.25)$0.75 million$0.64 millionViewN/AView Earnings Details
5/10/2017Q3 2017($0.13)($0.22)$0.90 million$1.32 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
11/4/2013Q1 2014($0.10)($0.05)$1.51 million$5.50 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
2/7/2013Q2 2013($0.09)($0.07)ViewN/AView Earnings Details
11/8/2012Q1 2013($0.08)($0.10)ViewN/AView Earnings Details
8/23/2012Q4 2012($0.08)($0.10)ViewN/AView Earnings Details
5/8/2012Q3 2012($0.08)($0.10)ViewN/AView Earnings Details
2/8/2012Q2 2012($0.08)$0.27ViewN/AView Earnings Details
11/4/2011Q1 2012($0.08)($0.07)ViewN/AView Earnings Details
8/24/2011Q4 2011($0.06)$0.03ViewN/AView Earnings Details
5/10/2011Q3 2011($0.06)($0.10)ViewN/AView Earnings Details
2/4/2011Q2 2011($0.08)($0.05)ViewN/AView Earnings Details
11/4/2010Q1 2011($0.07)($0.09)ViewN/AView Earnings Details
8/26/2010Q4 2010($0.08)$0.01ViewN/AView Earnings Details
5/10/2010Q3 2010($0.09)$0.05ViewN/AView Earnings Details
2/2/2010Q2 2010$0.03$0.01ViewN/AView Earnings Details
11/6/2009Q1 2010$0.43$0.42ViewN/AView Earnings Details
8/27/2009Q4 2009$0.01$0.01ViewN/AView Earnings Details
5/11/2009Q3 2009($0.01)$0.01ViewN/AView Earnings Details
2/9/2009Q2 2009($0.01)$0.04ViewN/AView Earnings Details
11/7/2008Q1 2009($0.03)ViewN/AView Earnings Details
8/28/2008Q4 2008($0.08)($0.09)ViewN/AView Earnings Details
5/7/2008Q3 2008($0.08)ViewN/AView Earnings Details
2/7/2008Q2 2008($0.09)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Immunomedics (NASDAQ:IMMU) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Immunomedics (NASDAQ IMMU) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.80%
Institutional Ownership Percentage: 74.51%
Insider Trading History for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Immunomedics (NASDAQ IMMU) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2018David M GoldenbergDirectorSell20,000$17.50$350,000.001,774,285View SEC Filing  
3/5/2018David M GoldenbergDirectorSell40,000$17.24$689,600.001,774,285View SEC Filing  
2/28/2018David M GoldenbergDirectorSell17,729$17.09$302,988.611,774,285View SEC Filing  
11/20/2017Brian A MarkisonDirectorSell8,390$11.89$99,757.1099,178View SEC Filing  
11/15/2017Behzad AghazadehInsiderBuy1,325,000$10.47$13,872,750.00View SEC Filing  
11/14/2017Venbio Select Advisor LlcDirectorBuy1,150,000$10.39$11,948,500.00View SEC Filing  
9/1/2017David M. GoldenbergInsiderSell20,000$12.64$252,800.00View SEC Filing  
8/28/2017Cynthia L. GoldenbergDirectorSell40,000$10.72$428,800.00View SEC Filing  
8/23/2017Cynthia L. GoldenbergDirectorSell40,000$9.24$369,600.00View SEC Filing  
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.0055,848View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.0082,474View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70650,396View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42703,029View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.802,602,063View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00703,029View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.002,602,063View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31703,029View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.982,602,063View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.0022,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Immunomedics (NASDAQ IMMU) News Headlines

Source:
DateHeadline
Immunomedics (IMMU) Upgraded at BidaskClubImmunomedics (IMMU) Upgraded at BidaskClub
www.americanbankingnews.com - April 20 at 11:39 AM
Immunomedics (IMMU) Rating Increased to Buy at Zacks Investment ResearchImmunomedics (IMMU) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 19 at 6:22 PM
Immunomedics (IMMU) Rating Lowered to Hold at Zacks Investment ResearchImmunomedics (IMMU) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:48 PM
 Brokerages Anticipate Immunomedics (IMMU) Will Announce Earnings of -$0.13 Per Share Brokerages Anticipate Immunomedics (IMMU) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - April 17 at 7:08 PM
When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable?When Will Immunomedics Inc (NASDAQ:IMMU) Become Profitable?
finance.yahoo.com - April 17 at 5:26 PM
BidaskClub Downgrades Immunomedics (IMMU) to BuyBidaskClub Downgrades Immunomedics (IMMU) to Buy
www.americanbankingnews.com - April 16 at 9:48 AM
Today’s Research Reports on Trending Tickers: Exact Sciences and ImmunomedicsToday’s Research Reports on Trending Tickers: Exact Sciences and Immunomedics
finance.yahoo.com - April 13 at 9:02 AM
Immunomedics Target of Unusually Large Options Trading (IMMU)Immunomedics Target of Unusually Large Options Trading (IMMU)
www.americanbankingnews.com - April 13 at 6:11 AM
Immunomedics (IMMU) Upgraded at ValuEngineImmunomedics (IMMU) Upgraded at ValuEngine
www.americanbankingnews.com - April 12 at 10:18 PM
Immunomedics (IMMU) Short Interest UpdateImmunomedics (IMMU) Short Interest Update
www.americanbankingnews.com - April 12 at 2:17 AM
Analyzing Intellia Therapeutics (NTLA) and Immunomedics (IMMU)Analyzing Intellia Therapeutics (NTLA) and Immunomedics (IMMU)
www.americanbankingnews.com - April 11 at 1:24 AM
Immunomedics (IMMU) Names Dr. Robert Iannone Head of Research & Development and CMOImmunomedics (IMMU) Names Dr. Robert Iannone Head of Research & Development and CMO
www.streetinsider.com - April 9 at 4:56 PM
Immunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical OfficerImmunomedics Appoints Dr. Robert Iannone Head of Research & Development and Chief Medical Officer
finance.yahoo.com - April 9 at 9:00 AM
Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Hold" by AnalystsImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 1 at 1:32 PM
 Brokerages Expect Immunomedics, Inc. (IMMU) Will Announce Earnings of -$0.13 Per Share Brokerages Expect Immunomedics, Inc. (IMMU) Will Announce Earnings of -$0.13 Per Share
www.americanbankingnews.com - March 31 at 7:14 PM
Immunomedics (IMMU) Rating Lowered to Buy at BidaskClubImmunomedics (IMMU) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - March 26 at 9:55 AM
Immunomedics (IMMU) Lifted to "Hold" at ValuEngineImmunomedics (IMMU) Lifted to "Hold" at ValuEngine
www.americanbankingnews.com - March 25 at 5:22 PM
Immunomedics (IMMU) Cut to "Hold" at BidaskClubImmunomedics (IMMU) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - March 17 at 12:05 PM
 Analysts Expect Immunomedics, Inc. (IMMU) to Announce -$0.13 EPS Analysts Expect Immunomedics, Inc. (IMMU) to Announce -$0.13 EPS
www.americanbankingnews.com - March 14 at 5:24 PM
David M. Goldenberg Sells 40,000 Shares of Immunomedics, Inc. (IMMU) StockDavid M. Goldenberg Sells 40,000 Shares of Immunomedics, Inc. (IMMU) Stock
www.americanbankingnews.com - March 12 at 10:28 PM
Immunomedics, Inc. (IMMU) Director David M. Goldenberg Sells 20,000 SharesImmunomedics, Inc. (IMMU) Director David M. Goldenberg Sells 20,000 Shares
www.americanbankingnews.com - March 12 at 10:26 PM
Immunomedics, Inc. (IMMU) Director Sells $302,988.61 in StockImmunomedics, Inc. (IMMU) Director Sells $302,988.61 in Stock
www.americanbankingnews.com - March 12 at 10:26 PM
Immunomedics, Inc. (IMMU) Sees Significant Decline in Short InterestImmunomedics, Inc. (IMMU) Sees Significant Decline in Short Interest
www.americanbankingnews.com - March 12 at 1:24 AM
Immunomedics, Inc. (IMMU) Receives Average Rating of "Buy" from AnalystsImmunomedics, Inc. (IMMU) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 7 at 1:50 PM
Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)Immunomedics to Present at Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 5 at 8:51 AM
Immunomedics to Present at Cowen and Company 38th Annual Health Care ConferenceImmunomedics to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 5 at 8:51 AM
Immunomedics, Inc. (IMMU) Stake Lessened by EAM Investors LLCImmunomedics, Inc. (IMMU) Stake Lessened by EAM Investors LLC
www.americanbankingnews.com - March 2 at 1:32 PM
Immunomedics (IMMU) Upgraded to Buy at BidaskClubImmunomedics (IMMU) Upgraded to Buy at BidaskClub
www.americanbankingnews.com - February 25 at 5:28 PM
-$0.13 EPS Expected for Immunomedics, Inc. (IMMU) This Quarter-$0.13 EPS Expected for Immunomedics, Inc. (IMMU) This Quarter
www.americanbankingnews.com - February 25 at 5:17 PM
Immunomedics (IMMU) Upgraded by TheStreet to C-Immunomedics (IMMU) Upgraded by TheStreet to C-
www.americanbankingnews.com - February 18 at 9:22 PM
Zacks Investment Research Downgrades Immunomedics (IMMU) to SellZacks Investment Research Downgrades Immunomedics (IMMU) to Sell
www.americanbankingnews.com - February 17 at 6:56 AM
Immunomedics to Participate in RBC Capital Markets 2018 Global Healthcare ConferenceImmunomedics to Participate in RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 8:20 AM
Reviewing Immunomedics (IMMU) and Arsanis (ASNS)Reviewing Immunomedics (IMMU) and Arsanis (ASNS)
www.americanbankingnews.com - February 15 at 3:18 AM
Blog Exposure - FDA Accepts Amicus Therapeutics’ NDA for Migalastat for Treatment of Fabry DiseaseBlog Exposure - FDA Accepts Amicus Therapeutics’ NDA for Migalastat for Treatment of Fabry Disease
finance.yahoo.com - February 14 at 9:33 AM
Immunomedics (IMMU) Raised to "Buy" at BidaskClubImmunomedics (IMMU) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - February 11 at 8:10 AM
Immunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by BrokeragesImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 10 at 1:58 PM
Immunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate UpdateImmunomedics Announces Second Quarter Fiscal 2018 Results and Provides Corporate Update
finance.yahoo.com - February 9 at 9:35 AM
Immunomedics reports 2Q lossImmunomedics reports 2Q loss
finance.yahoo.com - February 9 at 9:35 AM
Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018Immunomedics to Report Second Quarter Fiscal 2018 Results and Host Conference Call and Webcast on February 8, 2018
finance.yahoo.com - February 6 at 9:31 AM
Analyzing Ironwood Pharmaceuticals (IRWD) and Immunomedics (IMMU)Analyzing Ironwood Pharmaceuticals (IRWD) and Immunomedics (IMMU)
www.americanbankingnews.com - January 31 at 5:12 PM
Immunomedics (IMMU) Price Target Raised to $27.00Immunomedics (IMMU) Price Target Raised to $27.00
www.americanbankingnews.com - January 28 at 5:34 PM
BidaskClub Upgrades Immunomedics (IMMU) to Strong-BuyBidaskClub Upgrades Immunomedics (IMMU) to Strong-Buy
www.americanbankingnews.com - January 28 at 8:54 AM
Contrasting Celator Pharmaceuticals (CPXX) and Immunomedics (IMMU)Contrasting Celator Pharmaceuticals (CPXX) and Immunomedics (IMMU)
www.americanbankingnews.com - January 28 at 7:18 AM
Q3 2018 EPS Estimates for Immunomedics, Inc. Lifted by Analyst (IMMU)Q3 2018 EPS Estimates for Immunomedics, Inc. Lifted by Analyst (IMMU)
www.americanbankingnews.com - January 26 at 10:22 AM
Interesting IMMU Put And Call Options For March 16thInteresting IMMU Put And Call Options For March 16th
www.nasdaq.com - January 24 at 4:17 PM
Immunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by BrokeragesImmunomedics, Inc. (IMMU) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 16 at 2:08 PM
Short Sellers Fueling Runaway Bull Market By Racing To Buy Back StocksShort Sellers Fueling Runaway Bull Market By Racing To Buy Back Stocks
www.forbes.com - January 15 at 3:27 PM
Short Interest in Immunomedics, Inc. (IMMU) Expands By 6.3%Short Interest in Immunomedics, Inc. (IMMU) Expands By 6.3%
www.americanbankingnews.com - January 12 at 3:14 AM
BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate CancerBRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer
www.reuters.com - January 11 at 8:50 AM
Immunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate CancerImmunomedics Announces Agreement with University of Wisconsin Carbone Cancer Center to Expand Sacituzumab Govitecan (IMMU-132) into Prostate Cancer
finance.yahoo.com - January 11 at 8:50 AM

SEC Filings

Immunomedics (NASDAQ:IMMU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Immunomedics (NASDAQ:IMMU) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Immunomedics (NASDAQ IMMU) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.